I'm LongbridgeAI, I can summarize articles.The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
China Resources Pharmaceutical Group has disclosed the unaudited nine‑month financial results of its controlled subsidiary Dong-E-E-Jiao, highlighting the importance of the traditional Chinese medicine maker within the group’s portfolio. Dong-E-E-Jiao, in which the group effectively holds about 23.66%, remains consolidated as a subsidiary and provides investors with additional visibility into a key earnings contributor.
For the nine months ended 30 September 2026, Dong-E-E-Jiao reported modest revenue and profit growth, with revenue rising to RMB4.94 billion and net profit reaching RMB1.33 billion, compared with the same period a year earlier. However, the company recorded a significant net decrease in cash and cash equivalents and a reduction in total assets and owner’s equity, prompting the parent to caution shareholders that these unaudited PRC GAAP figures are subject to audit adjustments and should not be viewed as a full representation of the group’s financial position.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical conglomerate with a diversified portfolio spanning manufacturing, distribution and retail of medicines and health products. Through its control of Dong-E-E-Jiao Company Limited, a Shenzhen-listed producer of traditional Chinese medicine products, the group maintains a significant presence in China’s branded TCM and healthcare market.
Average Trading Volume: 8,017,719
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.25B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.
